mannkind corporation (nasdaq: mnkd) focuses on the discovery, development and commercialization of therapeutic products for patients with diseases such as diabetes and cancer. in addition, mannkind is applying our novel technologies and services to support partner development efforts.
Company profile
Ticker
MNKD
Exchange
Website
CEO
Michael Castagna
Employees
Incorporated
Location
Fiscal year end
Industry (SIC)
SEC CIK
Corporate docs
IRS number
133607736
MNKD stock data
Latest filings (excl ownership)
8-K
Departure of Directors or Certain Officers
26 Mar 24
10-K
2023 FY
Annual report
27 Feb 24
8-K
Results of Operations and Financial Condition
27 Feb 24
8-K
Purchase and Sale Agreement
2 Jan 24
8-K
Entry into a Material Definitive Agreement
27 Dec 23
10-Q
2023 Q3
Quarterly report
7 Nov 23
8-K
Mannkind Corporation Reports 2023 Third Quarter Financial Results
7 Nov 23
S-8
Registration of securities for employees
23 Aug 23
10-Q
2023 Q2
Quarterly report
7 Aug 23
8-K
Mannkind Corporation Reports 2023 Second Quarter Financial Results
7 Aug 23
Transcripts
MNKD
Earnings call transcript
2023 Q4
27 Feb 24
MNKD
Earnings call transcript
2023 Q3
7 Nov 23
MNKD
Earnings call transcript
2023 Q2
7 Aug 23
MNKD
Earnings call transcript
2023 Q1
9 May 23
MNKD
Earnings call transcript
2022 Q4
23 Feb 23
MNKD
Earnings call transcript
2022 Q3
8 Nov 22
MNKD
Earnings call transcript
2022 Q2
10 Aug 22
MNKD
Earnings call transcript
2022 Q1
6 May 22
MNKD
Earnings call transcript
2021 Q4
25 Feb 22
MNKD
Earnings call transcript
2021 Q3
10 Nov 21
Latest ownership filings
Financial summary
Quarter (USD) | Sep 23 | Jun 23 | Mar 23 | Dec 22 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Annual (USD) | Dec 22 | Dec 21 | Dec 20 | Dec 19 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Cash burn rate (est.) | Burn method: Change in cash | Burn method: Operating income | Burn method: FCF (opex + capex) | Last Q | Avg 4Q | Last Q | Avg 4Q | Last Q | Avg 4Q |
---|---|---|---|---|---|---|
Cash on hand (at last report) | 83.02 mm | 83.02 mm | 83.02 mm | 83.02 mm | 83.02 mm | 83.02 mm |
Cash burn (monthly) | 1.06 mm | (no burn) | (no burn) | 2.33 mm | (no burn) | (no burn) |
Cash used (since last report) | 6.28 mm | n/a | n/a | 13.82 mm | n/a | n/a |
Cash remaining | 76.74 mm | n/a | n/a | 69.19 mm | n/a | n/a |
Runway (months of cash) | 72.7 | n/a | n/a | 29.8 | n/a | n/a |
Institutional ownership, Q3 2023
56.1% owned by funds/institutions
13F holders | Current |
---|---|
Total holders | 196 |
Opened positions | 28 |
Closed positions | 15 |
Increased positions | 63 |
Reduced positions | 52 |
13F shares | Current |
---|---|
Total value | 570.08 bn |
Total shares | 151.82 mm |
Total puts | 547.40 k |
Total calls | 758.40 k |
Total put/call ratio | 0.7 |
Largest owners | Shares | Value |
---|---|---|
BLK Blackrock | 20.54 mm | $84.82 bn |
Vanguard | 14.65 mm | $60.50 bn |
STT State Street | 12.22 mm | $50.45 bn |
CVI Investments | 10.65 mm | $13.73 mm |
Nitorum Capital | 10.47 mm | $43.24 bn |
Avoro Capital Advisors | 9.00 mm | $37.17 bn |
FMR | 6.46 mm | $26.67 bn |
Geode Capital Management | 5.51 mm | $22.78 bn |
D. E. Shaw & Co. | 4.21 mm | $17.38 bn |
Millennium Management | 3.97 mm | $16.38 bn |
Recent insider trades
Date | Owner | Security | Transaction | Code | Indirect | 10b5-1 | $Price | #Shares | $Value | #Remaining |
---|---|---|---|---|---|---|---|---|---|---|
4 Feb 24 | Sabrina Kay | Common Stock, $0.01 Par Value | Grant | Acquire A | No | No | 3.27 | 107,033 | 350.00 k | 265,600 |
4 Feb 24 | Consiglio Ronald J | Common Stock, $0.01 Par Value | Grant | Acquire A | No | No | 3.27 | 25,000 | 81.75 k | 545,997 |
4 Feb 24 | Anthony C Hooper | Common Stock, $0.01 Par Value | Grant | Acquire A | No | No | 3.27 | 40,000 | 130.80 k | 176,153 |
4 Feb 24 | Burkhard Blank | Common Stock, $0.01 Par Value | Grant | Acquire A | No | No | 3.27 | 152,905 | 500.00 k | 367,905 |
4 Feb 24 | Lauren M Sabella | Common Stock, $0.01 Par Value | Grant | Acquire A | No | No | 3.27 | 15,290 | 50.00 k | 263,435 |
31 Dec 23 | Burkhard Blank | Common Stock, $0.01 Par Value | Grant | Acquire A | No | No | 3.09 | 5,000 | 15.45 k | 215,000 |
31 Dec 23 | Lauren M Sabella | Common Stock, $0.01 Par Value | Grant | Acquire A | No | No | 3.09 | 711 | 2.20 k | 248,145 |
News
Cantor Fitzgerald Reiterates Overweight on MannKind, Maintains $6.5 Price Target
15 Mar 24
Why Mesoblast Shares Are Trading Higher By 13%? Here Are Other Stocks Moving In Monday's Mid-Day Session
11 Mar 24
EQT, Genie Energy And Other Big Stocks Moving Lower On Monday
11 Mar 24
What's Going On With MannKind Stock?
11 Mar 24
MannKind Announced Initial Meal Challenge Data From INHALE-3 Phase 4 U.S. Trial Comparing Afrezza Head-to-head With Multiple Daily Injections And Insulin Pumps
11 Mar 24
Press releases
MannKind Announces CFO Transition
26 Mar 24
INHALE-3 Study's Initial Meal Challenge Results Comparing Afrezza® Head-To-Head With Multiple Daily Injections (MDI) and Insulin Pumps
11 Mar 24
MannKind Announces New Clinical Data From Inhale-3 Study to be Presented by Dr. Irl B. Hirsch at ATTD on March 8
5 Mar 24
MannKind Corporation Announces Participation at Upcoming Conferences
4 Mar 24
MannKind Corporation Reports 2023 Fourth Quarter and Full Year Financial Results: Provides Clinical Development Update
27 Feb 24